**Overview**
Trodelvy is an antibody drug conjugate antineoplastic agent indicated for the treatment of metastatic or refractory triple-negative breast cancer in adults who have received 2 or more prior therapies for metastatic disease.

**Coverage Guidelines**
Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with Trodelvy, excluding when the product is obtained as samples or via manufacturer’s patient assistance program

**OR**
Approval of Trodelvy will be granted if the member meets all following criteria and documentation has been submitted:
1. The member has been diagnosed with metastatic triple-negative breast cancer
2. The prescriber is an oncologist or medication is being used in consultation with an oncologist.
3. The member has had an inadequate response or adverse reaction to at least two prior therapies for metastatic disease

**Limitations**
Initial approvals and reauthorizations will be granted at 12-month intervals.

**References**

**Review History**
11/18/2020- Reviewed at P+T. Effective 1/1/21

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.